Life Science News

RSS

Introducing Evosep Proteomics to standardize and scale proteomics for research and drug development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

Cellular reprogramming helps outsmart progressive Alzheimers disease

A team led by researcher José Vicente Sánchez Mut at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the Miguel Hernández University of Elche (UMH), together with researcher Johannes Gräff at the École Polytechnique Fédérale de Lausanne (EPFL), has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their protective function against Alzheimer's disease.

2 Jun 2026

New blood test tracks real time gene expression inside living brain tissue

Cell function is determined by how DNA is expressed into proteins. That process includes two main steps - transcription, when messenger RNA (mRNA) makes copies of active genes, and translation, when mRNA guides protein assembly.

2 Jun 2026

Jumping genes help strengthen the mammalian Y chromosome

The humble Y chromosome may be the smallest chromosome in the mammalian genome (and getting even smaller), but it is mighty: genes on the Y chromosome are critical for fertility in males.

1 Jun 2026

PromptSE AI predicts drug side effects by reasoning through biological clues

PromptSE uses structured LLM prompting to generate pharmacologically relevant side-effect representations, then feeds them into deep learning models to predict drug-side effect associations. In benchmark testing, PromptSE improved prediction performance, while PromptSE+ further boosted results by adding multi-modal drug information and graph-based refinement for sparse data.

1 Jun 2026

Mature intestinal cells regain stem cell behavior to trigger tumor growth

In a groundbreaking study, Stevens researchers show how colorectal cancers can evolve from mature intestinal cells that revert to stem cells.

1 Jun 2026

New atlas provides unprecedented overview of dendritic cell diversity across cancers

Researchers from VIB, VUB, and an international network of collaborators have created the most comprehensive single-cell atlas to date of tumor-associated dendritic cells.

1 Jun 2026

New SMArT platform improves safety of CRISPR gene editing

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a new strategy to significantly improve the precision and safety of CRISPR-Cas9 gene editing in human blood stem cells, potentially overcoming one of the major barriers limiting broader clinical application of genome editing therapies.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

Millions live with undiagnosed heart rhythm disorders – World Heart Rhythm Week 2026 calls for urgent action

Millions of people worldwide are living with undiagnosed heart rhythm disorders that can lead to stroke, heart failure or sudden cardiac death – often with little or no warning.

1 Jun 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 1 Jun 2026

Mesenchymal drift may explain how aging cells lose their identity

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.

1 Jun 2026

Fruit fly study links dopamine to stress-induced sexual dysfunction

Scientists from Tokyo Metropolitan University have revealed key parts of the biochemical pathways connecting stress to sexual dysfunction.

30 May 2026

Tick protein discovery could help prevent disease transmission

Few creatures inspire as much universal dislike as ticks. Though small, these parasites have an enormous impact on human and animal health. Each year, ticks spread viruses and bacteria that infect people, livestock, wildlife and pets around the world.

29 May 2026

Structural insights reveal unique bacterial β-1,2-glucan transport system

Even though sugars are often framed as simple sources of energy, they also serve as structurally complex and functionally diverse molecules that mediate interactions between organisms.

29 May 2026

Gladstone scientists track exact routes used to clear brain waste

Think of the brain as if it were a house. Insulated from its environment, a house relies on complex networks-pipes, drains, and disposal systems-that interface with the outside world to keep the home functional on the inside.

29 May 2026

Novel therapeutic agent proposed to combat drug resistant tuberculosis

A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques.

29 May 2026

New approach helps design better antibiotics to fight drug-resistant infections

A new way of designing antibiotics could support the discovery of new treatments for drug-resistant infections.

29 May 2026

4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.

From 4basebio PLC 29 May 2026